Comparative Pharmacology
Head-to-head clinical analysis: LEVOTHYROXINE SODIUM INTRAVENOUS versus TIROSINT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOTHYROXINE SODIUM INTRAVENOUS versus TIROSINT.
LEVOTHYROXINE SODIUM vs TIROSINT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic T4 hormone that is deiodinated to T3, which binds to thyroid hormone receptors in the nucleus, regulating gene transcription and increasing metabolic rate.
Tirosint is a synthetic form of levothyroxine (T4), which is converted to triiodothyronine (T3) in peripheral tissues. T3 binds to thyroid hormone receptors in the nucleus, modulating gene transcription to increase metabolic rate, protein synthesis, and oxygen consumption.
Initial adult dose: 25-50 mcg orally once daily, titrated by 12.5-25 mcg every 6-8 weeks based on TSH. Usual maintenance: 1.6 mcg/kg/day. Route: oral; IV dose is 50% of oral dose.
Initial dose 1.6 mcg/kg orally once daily, adjusted based on TSH levels. Typical maintenance dose 50-200 mcg/day.
None Documented
None Documented
6-7 days (euthyroid); prolonged in hypothyroidism (9-10 days) and shortened in hyperthyroidism (3-4 days).
Terminal half-life approximately 7 days in euthyroid individuals; prolonged in hypothyroidism (up to 9-10 days) and shortened in hyperthyroidism (3-4 days). Clinical context: steady-state reached in 4-6 weeks; dosage adjustments require 6-8 weeks for full effect.
Renal (approximately 50% as unchanged drug and conjugates); fecal (biliary excretion of conjugates, ~20-30%); minor pulmonary and dermal routes.
Renal (approximately 30-40% as unchanged drug and metabolites, primarily glucuronide and sulfate conjugates); fecal (approximately 20-30% via bile); total clearance is low (~0.05 L/hr/kg).
Category A/B
Category C
Thyroid Hormone
Thyroid Hormone